Collagen Crosslinker Mixture TRI-1 TRI-2 TRI-3 Biostability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing collagen crosslinkers have limited biostability and are prone to degradation, which compromises their effectiveness in stabilizing collagen fibrils and protecting against collagenase-induced degradation.
Innovation Solution
Development of novel collagen crosslinking agents, TRI-1, TRI-2, and TRI-3, and their mixture, which exhibit enhanced biostability and rapid inhibition of collagenases, improving collagen fibril crosslinking and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional collagen crosslinkers are used to strengthen collagen fibrils, then collagen stability is improved, but biostability deteriorates due to degradation of the crosslinkers themselves
Solution Approach 1:
The patent applies composite materials by combining multiple crosslinking agents (TRI-1, TRI-2, TRI-3) with distinct mechanisms into a single formulation. TRI-1 provides rapid initial crosslinking, TRI-2 offers intermediate stability, and TRI-3 ensures long-term biostability. This composite approach allows the system to achieve both immediate collagen stabilization and sustained biostability over time, resolving the contradiction between rapid effect and long-term reliability.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure and properties of crosslinking agents to create a series with varying degradation rates and crosslinking strengths. By adjusting molecular weight, functional group composition, and hydrophobicity parameters across the TRI series, the formulation achieves both rapid initial action and prolonged stability, simultaneously improving collagen stability and biostability.
2Speed
If crosslinking agents are applied to rapidly stabilize collagen, then speed of action is improved, but biostability worsens due to reduced durability of the crosslinking effect
Solution Approach 1:
The patent applies preliminary action by incorporating multiple crosslinking agents with staggered activation and degradation profiles. TRI-1 acts immediately upon application to provide rapid initial stabilization, while TRI-2 and TRI-3 are designed to maintain and extend the crosslinking effect over subsequent days and weeks. This layered preliminary action ensures both rapid onset and prolonged duration of the crosslinking effect.
Solution Approach 2:
The patent employs periodic action through the sequential activation and degradation of different crosslinking agents in the TRI formulation. Each agent operates in a temporal sequence, with TRI-1 providing initial rapid crosslinking, followed by TRI-2 maintaining intermediate stability, and TRI-3 ensuring long-term durability. This periodic deployment of crosslinking mechanisms maintains continuous collagen stabilization throughout the treatment period.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel crosslinking agents and their mixture significantly enhance collagen stability, providing rapid and strong inhibition of collagenases, improved biostability, and compatibility with commercial dental adhesives without compromising their properties.
Implementation Method 1
chemical means (wherein the crosslinker directly covalently bonds with multiple fibrils to create 'bridges' that link those fibrils)
Implementation Method 2
The inhibition of collagenases can be directly inferred from the extent of collagen degradation upon exposure to collagenases
Data Source
AI summary
Crosslinking agents, TRI-1, TRI-2, and TRI-3, and/or a collagen crosslinking mixture comprising two or more of TRI-1, TRI-2 and TRI-3, are presented, as are the syntheses thereof. The collagen crosslinking effects of the mixture of TRI-1, TRI-2, and TRI-3 are significantly enhanced over any of the molecules taken individually. The mixture drastically improves collagen biostability, showing enhanced performance compared to commercially available collagen treatments, and acts quickly, requiring no more than 60 seconds to show inhibition of collagenases. The mixture is also nontoxic and has a slight beige color, which is aesthetically ideal for any treatment that may be visible to others. The collagen crosslinker mixture is furthermore shown to be mixable with commercial dental adhesive without compromising the desired properties of the crosslinkers or the adhesive.